Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Abramson Cancer Center at Penn Medicine
Memorial Sloan Kettering Cancer Center
Prescient Therapeutics, Ltd.
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
Soligenix
City of Hope Medical Center
Assistance Publique - Hôpitaux de Paris
Mayo Clinic
Kyowa Kirin Co., Ltd.
Columbia University
SciTech Development, Inc.
City of Hope Medical Center
University of Alabama at Birmingham
Barbara Ann Karmanos Cancer Institute
City of Hope Medical Center
City of Hope Medical Center
Mayo Clinic
Thomas Jefferson University
University College, London
4SC AG
Emory University
University of Pittsburgh
Indiana University
European Organisation for Research and Treatment of Cancer - EORTC
Stanford University
Stanford University
National Institutes of Health Clinical Center (CC)
European Organisation for Research and Treatment of Cancer - EORTC
University of Nebraska
Eastern Cooperative Oncology Group
Genmab
OncoSec Medical Incorporated
Genmab
Pfizer
Atara Biotherapeutics
Centre for Human Drug Research, Netherlands
Thomas Jefferson University
Elorac, Inc.
Sorrento Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
Soligenix
miRagen Therapeutics, Inc.
4SC AG
Assistance Publique - Hôpitaux de Paris